Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Pass Above 200-Day Moving Average – Here’s What Happened

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $4.28 and traded as high as $6.87. Cumberland Pharmaceuticals shares last traded at $6.48, with a volume of 38,864 shares.

Wall Street Analyst Weigh In

CPIX has been the topic of several recent research reports. Wall Street Zen lowered Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Cumberland Pharmaceuticals has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

The company has a quick ratio of 0.79, a current ratio of 0.95 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $95.42 million, a PE ratio of -13.00 and a beta of 0.09. The stock has a 50-day moving average price of $5.32 and a 200 day moving average price of $4.31.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The firm had revenue of $9.13 million for the quarter, compared to analysts’ expectations of $8.50 million. Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A number of large investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in shares of Cumberland Pharmaceuticals in the 2nd quarter worth $34,000. Arrowstreet Capital Limited Partnership acquired a new position in Cumberland Pharmaceuticals during the first quarter worth $66,000. Two Sigma Investments LP raised its holdings in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after buying an additional 5,326 shares during the period. Marshall Wace LLP acquired a new position in Cumberland Pharmaceuticals during the 4th quarter worth about $192,000. Finally, Geode Capital Management LLC boosted its holdings in Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after acquiring an additional 5,653 shares during the period. Hedge funds and other institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.